Alison Han, MD, MS

BS, Emory University
MS, Harvard School of Public Health
MD, Morehouse School of Medicine

Dr. Han completed her undergraduate degree at Emory University and received a Master of Science degree from the Harvard School of Public Health. She has three years of experience at the Georgia Department of Public Health working as an epidemiologist. She received her MD from Morehouse School of Medicine and completed a residency in internal medicine and pediatrics at University Hospitals Case Medical Center/Rainbow Babies and Children’s Hospital in Cleveland, Ohio.

She completed a clinical infectious diseases fellowship in the National Institute of Allergy and Infectious Diseases (NIAID) fellowship program. She is board-certified in general pediatrics, internal medicine, and infectious diseases. Dr. Han joined the NIAID Laboratory of Infectious Diseases (LID) Clinical Studies Unit first as a fellow and then as a staff clinician. Her research included influenza challenge in healthy volunteers and evaluating respiratory virus immunity after infection and vaccination.

Dr. Han joined the Clinical Center Hospital Epidemiology Service in 2023 leading a team of infection control consultants, an infectious diseases/antimicrobial stewardship pharmacist, and a program specialist.

She also collaborates with colleagues from NIAID and Children’s National Hospital in evaluating norovirus-specific T cells in patients with chronic norovirus infection.

• 2023 NIH Director’s Award NIH COVID-19 Treatment Guidelines Panel, 2023
• NIH Director’s Award COVID-19 Case Management System Group, 2022
• NIH Director’s Award COVID-19 Call Center, Contact Investigations Team, Positive Result Team, Serosurvey Team, 2021

Bean R, Giurgea LT, Han A, Czajkowski L, Cervantes-Medina A, Gouzoulis M, Mateja A, Hunsberger S, Reed S, Athota R, Baus HA, Kash JC, Park J, Taubenberger JK, Memoli MJ. Mucosal correlates of protection after influenza viral challenge of vaccinated and unvaccinated healthy volunteers. mBio. 2024;15:e02372-23.

Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Xiao Y, Gouzoulis M, Lumbard K, Hunsberger S, Reed S, Athota R, Baus HA, Lwin A, Sadoff J, Taubenberger JK, Memoli MJ. Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model. Clin Infect Dis. 2021 Dec 6;73(11):e4260-e4268.

Park JK, Xiao Y, Ramuta MD, Rosas LA, Fong S, Matthews AM, Freeman AD, Gouzoulis MA, Batchenkova NA, Yang X, Scherler K, Qi L, Reed S, Athota R, Czajkowski L, Han A, Morens DM, Walters KA, Memoli MJ, Kash JC, Taubenberger JK. Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model. Nat Med. 2020 Aug;26(8):1240-1246.

Manning JE, Oliveira F, Coutinho-Abreu IV, Herbert S, Meneses C, Kamhawi S, Baus HA, Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Athota R, Reed S, Mateja A, Hunsberger S, James E, Pleguezuelos O, Stoloff G, Valenzuela JG, Memoli MJ. Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial. Lancet. 2020 Jun 27;395(10242):1998-2007.

Han A, Czajkowski LM, Donaldson A, Baus HA, Reed SM, Athota RS, Bristol T, Rosas LA, Cervantes-Medina A, Taubenberger JK, Memoli MJ. A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model. Clin Infect Dis. 2019 Nov 27;69(12):2082-2090.

Han A, Poon JL, Powers JH 3rd, Leidy NK, Yu R, Memoli MJ. Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model. BMC Infect Dis. 2018 Jul 28;18(1):353.

Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT Jr, Taubenberger JK. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. mBio. 2016 Apr 19;7(2):e00417-16.